Xeris Biopharma Holdings Inc. (XERS), headquartered in Chicago, Illinois, is a prominent name in the field of pharmaceuticals, specializing in the development and commercialization of innovative, ready-to-use, and patient-friendly injectable and infusible drug formulations. The company’s proprietary XeriSol™ and XeriJect™ formulation technologies allow for the creation of ready-to-use liquid formulations of drugs that conventionally require reconstitution, refrigeration, constant agitation, or dilution.
Xeris Biopharma is well renowned for its novel approach to treating hypoglycemia, a critical condition often encountered in people living with diabetes. The company has shown its prowess in the industry by being the first to commercialize a ready-to-use, room-temperature stable glucagon, Gvoke®, for the emergency treatment of severe hypoglycemia. Gvoke® is available in both prefilled syringe (PFS) and autoinjector formats, providing fast and reliable treatment options for patients and caregivers in need.
Furthermore, XER-S3, Xeris’s developmental drug for the treatment of congenital hyperinsulinism, is in its Phases 2 and 3 and will further solidify its position as a market leader, providing pioneering solutions for those affected with this rare condition. Xeris’s commitment to deliver innovative and convenient drugs extends to other areas too, with diverse products under development in several therapeutic areas including epilepsy, adrenal insufficiency, and hypoglycemia.
Xeris Biopharma Holdings, Inc. operates on principles of developing breakthrough products which are patient-centric and bring convenience and effectiveness together. With a cutting-edge proprietary technology and an unyielding dedication to innovation, Xeris continues to strive for improving the lives of people with serious, chronic conditions and acute care needs.
The stock market recognizes Xeris Biopharma under the ticker symbol “XERS” on the NASDAQ Exchange. With a steady focus on its various research and development initiatives, Xeris has been able to secure its position in the competitive pharmaceuticals market, and continues on its dedicated path towards bringing effective, easy-to-use medication closer to those who need it. With robust growth strategies and continuous advancements in its proprietary technologies, Xeris Biopharma holds an optimistic future in the industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Xeris Biopharma Holdings, Inc. (XERS) is a healthcare company focusing on therapies for chronic endocrine and neurological diseases, with a market cap of $1.49 billion. Analysts project a 50.56% upside potential, with an average target price of $12.29, driven by robust revenue growth of 28.70%. The company is reinvesting earnings into growth initiatives, focusing on its commercialized treatments and pipeline development, despite currently having negative EPS.
Steven Pieper, CFO of Xeris Biopharma Holdings, Inc., sold 5,000 shares of the company's common stock on September 1, 2026, at $8.5 per share. This transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on August 18, 2025. Following the sale, Mr. Pieper directly owns 1,356,053 shares of Xeris Biopharma common stock.
Rice Hall James & Associates LLC has acquired a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), purchasing 300,791 shares valued at approximately $2.38 million in the second quarter. The article details other institutional investors' activities, Xeris Biopharma's financial performance, and recent insider trading. Despite mixed analyst ratings, the stock has shown upward movement, but the company missed EPS estimates in its latest quarterly report.
Xeris Biopharma Holdings (XERS) is gaining attention after tighter full-year revenue guidance and second-quarter results were released on August 6, 2026. The stock is considered 22.8% undervalued with a fair value of $11.14 per share, compared to its current price of $8.60. This valuation is supported by projected faster top-line growth, higher profit margins, and the anticipated launch of XP-8121 for hypothyroidism, despite widening losses being a concern for some.
Walleye Capital LLC has invested $4.84 million in Xeris Biopharma Holdings, Inc. by acquiring 611,296 shares in the second quarter, representing 0.35% of the company. Institutional investors collectively own 42.75% of Xeris. Despite reporting higher-than-expected revenue of $92.1 million, the company posted an adjusted loss of $0.18 per share, missing analyst estimates.
This article identifies Mission Produce, Xeris Biopharma Holdings, and Gold Royalty as three U.S. stocks currently trading below their estimated intrinsic value based on future cash flows. It provides an overview of each company's operations, estimated discount to fair value, and growth prospects, including forecasted earnings growth and recent financial performance. The analysis aims to help investors find potential opportunities for appreciation in a rising market.